Skip to content

CJC-1295 With DAC

Emerging evidence

CJC-1295 with DAC (drug-affinity complex) binds to albumin and extends half-life, producing sustained GH elevation. Suited for less frequent dosing. Not medical advice; consult a provider.

How CJC-1295 With DAC works

CJC-1295 with DAC binds to albumin and releases over days, producing sustained GH elevation. Differs from no-DAC pulsatile approach. Provider oversight essential.

Researched benefits

  • •Sustained GH elevation; less frequent dosing
  • •Longer half-life than no-DAC variant
  • •Research in body composition and recovery
  • •Some protocols use weekly or twice-weekly dosing

What it is studied for

  • •GH support when sustained elevation is desired
  • •Convenience of less frequent dosing in some protocols
  • •Provider-directed use in research contexts

Reported side effects and cautions

  • •Injection-site reactions
  • •Sustained GH may increase side-effect profile; monitoring important
  • •Not for active cancer or certain conditions

Dosing protocol described in the literature

Dosage
250-500mcg
Frequency
With Ipamorelin
Administration
Subcutaneous
Cycle
8-16 weeks

GH optimization

Work out the reconstitution for this dose →

Evidence rating: Emerging evidence

Some human data exists but the evidence base is limited — often small studies, narrow indications, or trials still under way.

Other peptides

BPC157TB500 (Thymosin B4 Acetate)Semaglutide (Ozempic / Wegovy)Tirzepatide (GLP-1/GIP dual agonist)CagrilintideRetatrutide + Cagrilintide (combination)

See every peptide in the library →

Educational information only. This page is not medical advice, not a prescription, and not a recommendation to use CJC-1295 With DAC. Dosing figures describe what appears in published research and provider protocols — they are not instructions. Several compounds covered here are prescription medicines. Talk to a licensed healthcare provider before acting on anything you read.